Bio-Rad Laboratories (BIO) reported Q4 adjusted net income late Thursday of $2.90 per diluted share, down from $3.10 a year ago.
Analysts polled by FactSet expected $2.87.
Revenue for the quarter that ended Dec. 31 was $667.5, down from $681.2 million a year ago.
Analysts surveyed by FactSet expected $679.3 million.
For 2025, the company expects non-GAAP, currency-neutral revenue growth of 1.5% to 3.5% and non-GAAP operating margin of 13.0% to 13.5%.
Bio-Rad shares were down about 4% in extended trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.